Optimal Thiotepa Exposure Is Associated with Improved Rejection and Non-Relapse Mortality in Pediatric Patients Undergoing Alpha-Beta-T-cell/CD19-Depleted Haploidentical HCT for Hematologic Malignancy

Key Points

• Improved non-relapse mortality is associated with optimal thiotepa exposure in pediatric patients undergoing haploidentical HCT.
• Research indicates a significant linkage between thiotepa dosage and better rejection rates, providing key insights for treatment.
• Assessment of treatment outcomes highlights the importance of thiotepa during haploidentical HCT for hematologic malignancy.
• Findings suggest that optimized thiotepa dosing could enhance recovery prospects, warranting further exploration in clinical settings.